Machine learning vs. field 3D-QSAR models for serotonin 2A receptor psychoactive substances identification

Five QSAR models for predicting the affinity of 5-HT2AR ligands have been developed. The resulting models generate a useful tool for the investigation and identification of unclassified new psychoactive substances (NPS).

[1]  Be Vang Dean,et al.  2C or Not 2C: Phenethylamine Designer Drug Review , 2013, Journal of Medical Toxicology.

[2]  D. E. Nichols,et al.  Structure of a Hallucinogen-Activated Gq-Coupled 5-HT2A Serotonin Receptor , 2020, Cell.

[3]  T. Roth,et al.  APD125, a selective serotonin 5-HT(2A) receptor inverse agonist, significantly improves sleep maintenance in primary insomnia. , 2008, Sleep.

[4]  E. V. van Puijenbroek,et al.  Mirtazapine-induced arthralgia. , 2005, British journal of clinical pharmacology.

[5]  J. Lehmann,et al.  Dibenzazecine compounds with a novel dopamine/5HT2A receptor profile and 3D-QSAR analysis , 2006, BMC pharmacology.

[6]  Xin Li,et al.  Characterization of Three Novel Fatty Acid- and Retinoid-Binding Protein Genes (Ha-far-1, Ha-far-2 and Hf-far-1) from the Cereal Cyst Nematodes Heterodera avenae and H. filipjevi , 2016, PloS one.

[7]  R. Westerink,et al.  Effect fingerprinting of new psychoactive substances (NPS): What can we learn from in vitro data? , 2017, Pharmacology & therapeutics.

[8]  V. Abbate,et al.  3D-QSAR assisted identification of FABP4 inhibitors: An effective scaffold hopping analysis/QSAR evaluation. , 2019, Bioorganic chemistry.

[9]  S. Wold,et al.  PLS-regression: a basic tool of chemometrics , 2001 .

[10]  J. Harvey,et al.  Role of the serotonin 5-HT(2A) receptor in learning. , 2003, Learning & memory.

[11]  L. Salerno,et al.  Identification of Potentially Potent Heme Oxygenase 1 Inhibitors through 3D‐QSAR Coupled to Scaffold‐Hopping Analysis , 2018, ChemMedChem.

[12]  R. Turnaturi,et al.  A Structure- and Ligand-Based Virtual Screening of a Database of “Small” Marine Natural Products for the Identification of “Blue” Sigma-2 Receptor Ligands , 2018, Marine drugs.

[13]  S. Fallarini,et al.  In silico-driven multicomponent synthesis of 4,5- and 1,5-disubstituted imidazoles as indoleamine 2,3-dioxygenase inhibitors , 2016 .

[14]  David E. Nichols,et al.  Psychedelics , 2016, Pharmacological Reviews.

[15]  K. Pueschel,et al.  Mass poisoning with NPS: 2C-E and Bromo-DragonFly , 2018, International Journal of Legal Medicine.

[16]  K. Nikolić,et al.  In silico identification of novel 5-HT2A antagonists supported with ligand- and target-based drug design methodologies , 2020, Journal of biomolecular structure & dynamics.

[17]  W. Harding,et al.  Aporphine Alkaloids as Ligands for Serotonin Receptors , 2016 .

[18]  Vincenzo Abbate,et al.  Structure-Based Approach for the Prediction of Mu-opioid Binding Affinity of Unclassified Designer Fentanyl-Like Molecules , 2019, International journal of molecular sciences.

[19]  J. Dinges,et al.  Bioactive Carboxylic Compound Classes: Pharmaceuticals and Agrochemicals: Pharmaceuticals and Agrochemicals , 2016 .

[20]  V. Abbate,et al.  Discovery of High-Affinity Cannabinoid Receptors Ligands through a 3D-QSAR Ushered by Scaffold-Hopping Analysis † , 2018, Molecules.

[21]  Xin Zhao,et al.  Comparative Molecular Field Analysis (CoMFA) and Comparative Molecular Similarity Indices Analysis (CoMSIA) Studies on α1A-Adrenergic Receptor Antagonists Based on Pharmacophore Molecular Alignment , 2011, International journal of molecular sciences.

[22]  S. D. Jong.  SIMPLS: an alternative approach to partial least squares regression , 1993 .

[23]  S. Iwata,et al.  Structures of the 5-HT2A receptor in complex with the antipsychotics risperidone and zotepine , 2019, Nature Structural & Molecular Biology.

[24]  Anil K. Saxena,et al.  Consensus Superiority of the Pharmacophore-Based Alignment, Over Maximum Common Substructure (MCS): 3D-QSAR Studies on Carbamates as Acetylcholinesterase Inhibitors , 2009, J. Chem. Inf. Model..

[25]  S. Iwata,et al.  Structures of the 5-HT2A receptor in complex with the antipsychotics risperidone and zotepine , 2019, Nature Structural & Molecular Biology.

[26]  G. Martinotti,et al.  New psychoactive substances (NPS) and serotonin syndrome onset: A systematic review , 2021, Experimental Neurology.

[27]  R. Pertwee.  Pharmacology of cannabinoid CB1 and CB2 receptors. , 1997, Pharmacology & therapeutics.

[28]  N. Sharif,et al.  AL-34662: a potent, selective, and efficacious ocular hypotensive serotonin-2 receptor agonist. , 2007, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[29]  A. Tropsha,et al.  Beware of q2! , 2002, Journal of molecular graphics & modelling.

[30]  Ferran Sanz,et al.  New serotonin 5-HT(2A), 5-HT(2B), and 5-HT(2C) receptor antagonists: synthesis, pharmacology, 3D-QSAR, and molecular modeling of (aminoalkyl)benzo and heterocycloalkanones. , 2002, Journal of medicinal chemistry.

[31]  Baland Jalal.  The neuropharmacology of sleep paralysis hallucinations: serotonin 2A activation and a novel therapeutic drug , 2018, Psychopharmacology.

[32]  E. Maréchal.  Measuring Bioactivity: KI, IC50 and EC50 , 2011 .

[33]  James J P Stewart,et al.  Optimization of parameters for semiempirical methods IV: extension of MNDO, AM1, and PM3 to more main group elements , 2004, Journal of molecular modeling.

[34]  Carlos Aleman,et al.  Suitability of the PM3‐derived molecular electrostatic potentials , 1993, J. Comput. Chem..

[35]  T. Gray,et al.  5-HT2A Receptors Stimulate ACTH, Corticosterone, Oxytocin, Renin, and Prolactin Release and Activate Hypothalamic CRF and Oxytocin-Expressing Cells , 2001, The Journal of Neuroscience.

[36]  C. Stove,et al.  In vitro structure–activity relationship determination of 30 psychedelic new psychoactive substances by means of β-arrestin 2 recruitment to the serotonin 2A receptor , 2020, Archives of Toxicology.

[37]  A. Rescifina,et al.  An Integrated Pharmacophore/Docking/3D-QSAR Approach to Screening a Large Library of Products in Search of Future Botulinum Neurotoxin A Inhibitors , 2020, International journal of molecular sciences.

[38]  F. Khan,et al.  3D-QSAR studies on Maslinic acid analogs for Anticancer activity against Breast Cancer cell line MCF-7 , 2017, Scientific Reports.

[39]  P. Roy,et al.  Exploring the impact of size of training sets for the development of predictive QSAR models , 2008 .

[40]  T. Hirota,et al.  Development of Small-Molecule Cryptochrome Stabilizer Derivatives as Modulators of the Circadian Clock , 2015, ChemMedChem.

[41]  Andy Vinter,et al.  Molecular Field Extrema as Descriptors of Biological Activity: Definition and Validation , 2006, J. Chem. Inf. Model..

[42]  Gui-xiang Hu,et al.  3D-QSAR and 3D-QSSR studies of thieno[2,3-d]pyrimidin-4-yl hydrazone analogues as CDK4 inhibitors by CoMFA analysis , 2014, Acta Pharmacologica Sinica.

[43]  G. Knudsen,et al.  Current radiosynthesis strategies for 5-HT2A receptor PET tracers. , 2015, Journal of labelled compounds & radiopharmaceuticals.

[44]  C. Nichols,et al.  Serotonin 5-HT2A Receptor Activation Blocks TNF-α Mediated Inflammation In Vivo , 2013, PloS one.

[45]  D. E. Nichols,et al.  Chemistry and Structure-Activity Relationships of Psychedelics. , 2018, Current topics in behavioral neurosciences.

[46]  M. Liechti,et al.  Designer drugs: mechanism of action and adverse effects , 2020, Archives of Toxicology.

[47]  T. Lundbäck,et al.  N-Benzyl-indolo carboxylic acids: Design and synthesis of potent and selective adipocyte fatty-acid binding protein (A-FABP) inhibitors. , 2009, Bioorganic & medicinal chemistry letters.

[48]  E H Cook,et al.  Primary Structure of the Human Platelet Serotonin 5‐HT2A Receptor: Identity with Frontal Cortex Serotonin 5‐HT2A Receptor , 1994, Journal of neurochemistry.

[49]  P. Frati,et al.  NBOMe: new potent hallucinogens--pharmacology, analytical methods, toxicities, fatalities: a review. , 2015, European review for medical and pharmacological sciences.

[50]  V. Sorrenti,et al.  Development of new HO-1 inhibitors by a thorough scaffold-hopping analysis. , 2018, Bioorganic chemistry.